A138610 Stock Overview
A healthcare company, engages in the manufacture and sale of dental bone grafts and tissue regenerative collagen products in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
NIBEC Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩16,320.00 |
| 52 Week High | ₩25,850.00 |
| 52 Week Low | ₩13,740.00 |
| Beta | 0.90 |
| 1 Month Change | 18.43% |
| 3 Month Change | -5.06% |
| 1 Year Change | -26.49% |
| 3 Year Change | -38.18% |
| 5 Year Change | 47.03% |
| Change since IPO | 28.00% |
Recent News & Updates
More Unpleasant Surprises Could Be In Store For NIBEC Co., Ltd.'s (KOSDAQ:138610) Shares After Tumbling 34%
Nov 13
Does NIBEC (KOSDAQ:138610) Have A Healthy Balance Sheet?
Oct 14Is NIBEC (KOSDAQ:138610) Weighed On By Its Debt Load?
Jun 18NIBEC Co., Ltd.'s (KOSDAQ:138610) Share Price Not Quite Adding Up
Mar 28Recent updates
More Unpleasant Surprises Could Be In Store For NIBEC Co., Ltd.'s (KOSDAQ:138610) Shares After Tumbling 34%
Nov 13Does NIBEC (KOSDAQ:138610) Have A Healthy Balance Sheet?
Oct 14Is NIBEC (KOSDAQ:138610) Weighed On By Its Debt Load?
Jun 18NIBEC Co., Ltd.'s (KOSDAQ:138610) Share Price Not Quite Adding Up
Mar 28NIBEC (KOSDAQ:138610) Has Debt But No Earnings; Should You Worry?
Apr 05NIBEC (KOSDAQ:138610) Has Rewarded Shareholders With An Exceptional 411% Total Return On Their Investment
Jan 04Shareholder Returns
| A138610 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 4.2% | -3.9% | -3.7% |
| 1Y | -26.5% | 15.6% | -10.4% |
Return vs Industry: A138610 underperformed the KR Biotechs industry which returned 15.6% over the past year.
Return vs Market: A138610 underperformed the KR Market which returned -10.4% over the past year.
Price Volatility
| A138610 volatility | |
|---|---|
| A138610 Average Weekly Movement | 13.4% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A138610's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A138610's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Chongpyoung Chung | nibec.co.kr |
NIBEC Co., Ltd., a healthcare company, engages in the manufacture and sale of dental bone grafts and tissue regenerative collagen products in South Korea and internationally. It offers dental ointment, peptide containing dental bone graft materials, regenerative biomaterials, tooth whitening, tooth desensitizer, herbal toothpaste, and cosmetic products. The company was founded in 2000 and is headquartered in Jincheon-gun, South Korea.
NIBEC Co., Ltd. Fundamentals Summary
| A138610 fundamental statistics | |
|---|---|
| Market cap | ₩177.78b |
| Earnings (TTM) | -₩7.85b |
| Revenue (TTM) | ₩22.81b |
7.8x
P/S Ratio-22.7x
P/E RatioIs A138610 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A138610 income statement (TTM) | |
|---|---|
| Revenue | ₩22.81b |
| Cost of Revenue | ₩10.62b |
| Gross Profit | ₩12.19b |
| Other Expenses | ₩20.04b |
| Earnings | -₩7.85b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -720.42 |
| Gross Margin | 53.43% |
| Net Profit Margin | -34.40% |
| Debt/Equity Ratio | 89.2% |
How did A138610 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 03:47 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NIBEC Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|